Castro, Pedro
Palomo, Marta
Moreno-Castaño, Ana Belen
Fernández, Sara
Torramadé-Moix, Sergi
Pascual, Georgina
Martinez-Sanchez, Julia
Richardson, Edward
Téllez, Adrián
Nicolas, Josep M.
Carreras, Enric
Richardson, Paul G.
Badimon, Juan José
Escolar, Gines
Diaz-Ricart, Maribel http://orcid.org/0000-0003-1122-0052
Funding for this research was provided by:
Fundació Clínic (HCB/2020/0401)
Jazz Pharmaceuticals (IST-16-10355)
José Carreras Leukämie-Stiftung (03R/2019)
Instituto de Salud Carlos III (PI19/00888)
Fundació la Marató de TV3 (202026-10)
Bristol-Myers Squibb (ERISTA15)
Generalitat de Catalunya (2017-SGR671)
CERCA Program
Article History
Accepted: 24 May 2021
First Online: 7 June 2021
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: PC and SF have collaborated with Jansen, Gilead, Kite, MSD, Alexion, and Pfizer, outside of the submitted work. ABMC is an advisory board member for Siemens, outside of the submitted work. MDR and EC have been granted by and received honoraria from Jazz Pharmaceuticals. PGR has served on advisory committees for Jazz Pharmaceuticals. The rest of the coauthors have no actual or potential conflict of interest to declare.
Free to read: This content has been made available to all.